Our goal at the Rotman Research Institute (RRI) is to conduct research that will help current and future generations navigate the journey of aging, including Alzheimer’s disease and other dementias, along the smoothest and most optimal course. Our work aims to delay or prevent dementia altogether, to treat it through behavioural and pharmacological interventions, and to lessen its impact on the lives of patients and their caregivers. We do this through both foundational and translational science.
By furthering our understanding of aging and the human brain, foundational research at the RRI is critical in helping us identify differences in cognition between those who develop dementia and those who do not. Translating this knowledge, the Anne & Allan Bank Centre for Clinical Research Trials at Baycrest serves as a hub for the development and validation of emerging diagnostic tools and treatments for age-related neurodegenerative diseases. Baycrest is also the national scientific headquarters for the Canadian Consortium on Neurodegeneration in Aging (CCNA), which aims to maximize the coordination and impact of dementia research across Canada.